PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Last updated: October 17, 2025
Sponsor: Boehringer Ingelheim
Overall Status: Completed

Phase

N/A

Condition

Warts

Scalp Disorders

Psoriasis And Psoriatic Disorders

Treatment

Spesolimab

Clinical Study ID

NCT05670821
1368-0093
  • Ages > 18
  • All Genders

Study Summary

Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.)Infusion in Japan

  • Patients who have never been treated with Spesolimab I.V. Infusion before enrolment

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 52
Treatment Group(s): 1
Primary Treatment: Spesolimab
Phase:
Study Start date:
April 18, 2023
Estimated Completion Date:
October 06, 2025

Connect with a study center

  • Nippon Boehringer Ingelheim Co., Ltd.

    Tokyo, 1416017
    Japan

    Site Not Available

  • Nippon Boehringer Ingelheim Co., Ltd.

    Tokyo 1850147, 1416017
    Japan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.